Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals, a US based developer of cancer, CNS disorders, sexual dysfunction therapeutics, has received a US patent no. 7,998,991 for CNS-based treatment of sexual dysfunction.
Subscribe to our email newsletter
The new patent entitled, ‘Neurotherapeutic treatment for sexual dysfunction,’ includes a method to treat erectile dysfunction and premature ejaculation in males, as well as enhancing libido in females.
Currently, the company has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel.
Rexahn president Rick Soni said the company is making progress in the development of Zoraxel, currently in Phase II trials for erectile dysfunction.